Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 359 Endometrial Neoplasms 207 Uterine Cervical Neoplasms 187 Breast Neoplasms 109 Fallopian Tube Neoplasms 96 Colorectal Neoplasms 83 Carcinoma, Non-Small-Cell Lung 76 Neoplasms 65 Pancreatic Neoplasms 59 Stomach Neoplasms 55 Neoplasm Metastasis 51 Prostatic Neoplasms 50 Lung Neoplasms 46 Melanoma 43 Carcinoma, Ovarian Epithelial 41 Triple Negative Breast Neoplasms 38 Squamous Cell Carcinoma of Head and Neck 36 Esophageal Neoplasms 35 Carcinoma, Renal Cell 35 Colonic Neoplasms 31 Urinary Bladder Neoplasms 30 Peritoneal Neoplasms 29 Head and Neck Neoplasms 28 Vulvar Neoplasms 26 Uterine Neoplasms 26 Carcinoma, Hepatocellular 26 Carcinoma, Transitional Cell 24 Small Cell Lung Carcinoma 23 Sarcoma 20 Rectal Neoplasms 19

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Gynecologic × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡